- Home
- GO vs ARDX Comparison
GO vs ARDX Comparison
Compare GO & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GO
- ARDX
- Stock Information
- Founded
- GO 1946
- ARDX 2007
- Country
- GO United States
- ARDX United States
- Employees
- GO N/A
- ARDX N/A
- Industry
- GO Food Chains
- ARDX Biotechnology: Pharmaceutical Preparations
- Sector
- GO Consumer Staples
- ARDX Health Care
- Exchange
- GO Nasdaq
- ARDX Nasdaq
- Market Cap
- GO 1.6B
- ARDX 1.3B
- IPO Year
- GO 2019
- ARDX 2014
- Fundamental
- Price
- GO $13.54
- ARDX $4.72
- Analyst Decision
- GO Hold
- ARDX Strong Buy
- Analyst Count
- GO 12
- ARDX 9
- Target Price
- GO $16.08
- ARDX $10.61
- AVG Volume (30 Days)
- GO 2.6M
- ARDX 3.9M
- Earning Date
- GO 05-06-2025
- ARDX 05-01-2025
- Dividend Yield
- GO N/A
- ARDX N/A
- EPS Growth
- GO N/A
- ARDX N/A
- EPS
- GO 0.40
- ARDX N/A
- Revenue
- GO $4,371,501,000.00
- ARDX $333,615,000.00
- Revenue This Year
- GO $11.52
- ARDX $14.26
- Revenue Next Year
- GO $6.44
- ARDX $32.49
- P/E Ratio
- GO $33.14
- ARDX N/A
- Revenue Growth
- GO 10.13
- ARDX 168.06
- 52 Week Low
- GO $10.26
- ARDX $4.32
- 52 Week High
- GO $28.98
- ARDX $9.33
- Technical
- Relative Strength Index (RSI)
- GO 49.86
- ARDX 36.31
- Support Level
- GO $12.13
- ARDX $5.00
- Resistance Level
- GO $12.97
- ARDX $5.56
- Average True Range (ATR)
- GO 0.63
- ARDX 0.25
- MACD
- GO 0.22
- ARDX -0.06
- Stochastic Oscillator
- GO 83.52
- ARDX 3.79
About GO Grocery Outlet Holding Corp.
Grocery Outlet Holding Corp is a grocery store operator in the United States. Its flexible buying model allows them to offer quality, name-brand opportunistic products at prices generally 40% to 70% below those of conventional retailers. The stores are run by Entrepreneurial independent operators which create a neighborhood feel through personalized customer service and a localized product offering.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.